A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer

被引：0
|
作者：
Bangyou Zuo
Xiaobo Yang
Xu Yang
Jin Bian
Junyu Long
Dongxu Wang
Cong Ning
Yanyu Wang
Ziyu Xun
Yunchao Wang
Xin Lu
Yilei Mao
Xinting Sang
Haitao Zhao
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC),Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Gallbladder cancer; PD-1; Lenvatinib; PD-L1 expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1889 / 1896
页数：7
相关论文
共 50 条
  • [1] A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
    Zuo, Bangyou
    Yang, Xiaobo
    Yang, Xu
    Bian, Jin
    Long, Junyu
    Wang, Dongxu
    Ning, Cong
    Wang, Yanyu
    Xun, Ziyu
    Wang, Yunchao
    Lu, Xin
    Mao, Yilei
    Sang, Xinting
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 1889 - 1896
  • [2] Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
    Liu, Qingyan
    Li, Rong
    Li, Lingling
    Wang, Gaokun
    Ji, Shiyu
    Zheng, Xuan
    Jia, Xiaodong
    Tao, Haitao
    Hu, Yi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [3] Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients
    Zou, Jixue
    Huang, Peixin
    Ge, Ningling
    Xu, Xin
    Wang, Yanhong
    Zhang, Lan
    Chen, Yi
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1898 - 1906
  • [4] Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
    Li, Q.
    Chen, M.
    Cao, M.
    Yuan, G.
    Hu, X.
    Dai, W.
    Zang, M.
    Cheng, X.
    Huang, J.
    Hou, J.
    Chen, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1310 - S1310
  • [5] Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ge, Ning-Ling
    Chen, Yi
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer
    Tan, Yang
    Liu, Kai
    Zhu, Chengpei
    Wang, Shanshan
    Wang, Yunchao
    Xue, Jingnan
    Ning, Cong
    Zhang, Nan
    Chao, Jiashuo
    Zhang, Longhao
    Long, Junyu
    Yang, Xiaobo
    Zeng, Daobing
    Zhao, Lijin
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)
  • [7] Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).
    Nakamura, Yasuhiro
    Namikawa, Kenjiro
    Yoshino, Koji
    Yoshikawa, Shusuke
    Uchi, Hiroshi
    Goto, Katsunobu
    Nakamura, Yoshiyuki
    Fukushima, Satoshi
    Kiniwa, Yukiko
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Kawai, Toru
    Hatta, Naohito
    Funakoshi, Takeru
    Teramoto, Yukiko
    Otsuka, Atsushi
    Doi, Haruki
    Ogata, Dai
    Matsushita, Shigeto
    Yamazaki, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer
    Yang Tan
    Kai Liu
    Chengpei Zhu
    Shanshan Wang
    Yunchao Wang
    Jingnan Xue
    Cong Ning
    Nan Zhang
    Jiashuo Chao
    Longhao Zhang
    Junyu Long
    Xiaobo Yang
    Daobing Zeng
    Lijin Zhao
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 74 (6)
  • [9] Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
    Umeda, Yoshiyasu
    Yoshikawa, Shusuke
    Kiniwa, Yukiko
    Maekawa, Takeo
    Yamasaki, Osamu
    Isei, Taiki
    Matsushita, Shigeto
    Nomura, Motoo
    Nakai, Yasuo
    Fukushima, Satoshi
    Saito, Shintaro
    Takenouchi, Tatsuya
    Tanaka, Ryo
    Kato, Hiroshi
    Otsuka, Atsushi
    Matsuya, Taisuke
    Baba, Natsuki
    Nagase, Kotaro
    Inozume, Takashi
    Onuma, Takehiro
    Kuwatsuka, Yutaka
    Fujimoto, Noriki
    Kaneko, Takahide
    Onishi, Masazumi
    Namikawa, Kenjiro
    Yamazaki, Naoya
    Nakamura, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 361 - 372
  • [10] EFFICACY AND SAFETY OF LENVATINIB COMBINED WITH DIFFERENT ANTI-PD-1 ANTIBODY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A REAL WORLD EVIDENCE BASED RETROSPECTIVE STUDY
    Chen, Bowen
    Zhang, Linzhi
    Cheng, Jiamin, Sr.
    Yan, Tao
    Lu, Yinying
    HEPATOLOGY, 2021, 74 : 637A - 638A
12345